<DOC>
	<DOC>NCT01960179</DOC>
	<brief_summary>Primary Objective: To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks in patients with type 2 diabetes in Japan Secondary Objective: To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks on: - HbA1c (Glycated hemoglobin A1c) reduction; - Fasting plasma glucose; - Body weight.</brief_summary>
	<brief_title>Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes</brief_title>
	<detailed_description>- Group 1: 60 weeks ± 11 days - Group 2: 32 weeks ± 7 days</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Patients with type 2 diabetes mellitus diagnosed for at least 2 months. Not treated with antidiabetic drug or treated with a stable dose of 1 oral antidiabetic drug (OAD) for at least 3 months prior to screening visit. Previous OAD (if any) have to be stopped at Visit 1.1 to be washed out during the runin period at least for 6 weeks; Signed written informed consent. Exclusion criteria: At screening age &lt;20 years; HbA1c &lt;7% or &gt;9.5% (for patients on OAD &lt;6.5% or &gt;8.5%); fasting plasma glucose &gt;250 mg/dL (&gt;13.9 mmol/L); Use of more than one OAD within 3 months prior to screening; Use of Thiazolidinedione (TZD) within 6 months prior to screening; Use of insulin within 3 months prior to screening; Note: Short time use (≤10 days) of insulin due to acute illness or surgery (eg, infectious disease) is allowed. Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist; Type 1 diabetes mellitus Women of childbearing potential with no effective contraceptive method; Pregnancy or lactation; Laboratory findings at the time of screening: oAmylase and/or lipase &gt;3 times the upper limit of the normal laboratory range (ULN); ALT &gt;3 ULN; Calcitonin ≥20 pg/mL (5.9 pmol/L); Positive serum pregnancy test in women of childbearing potential; History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease; Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes); Allergic reaction to metacresol. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>